Good news on the Janssen vaccine...
A single-dose vaccine, made by the US company Johnson & Johnson, is 100 per cent effective at preventing deaths and hospitalisations from Covid-19.
This means that one month after vaccination, no one who received the vaccine was admitted to hospital or died, regardless of which strain of coronavirus they were exposed to.
In the 44,000-person trial by the company's subsidiary Janssen, based in the Netherlands, they also found the vaccine prevented 66 per cent of moderate to severe cases of Covid-19.
The UK has ordered 30m doses of the Janssen vaccine.
The jab worked across multiple variants of coronavirus, including the South African variant which has been worrying scientists, the firm said.
Responding to the news about the successful trial of the Johnson & Johnson vaccine, Health Secretary Matt Hancock tweeted: "This is yet more good news from Janssen on vaccines. If this jab is approved this could significantly bolster our vaccination programme, especially as a single-dose vaccine."